Share on StockTwits

Shares of McKesson (NYSE:MCK) have received a consensus recommendation of “Buy” from the seventeen brokerages that are presently covering the company, Analyst RN reports. Three investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $209.06.

Shares of McKesson (NYSE:MCK) opened at 189.83 on Tuesday. McKesson has a 52-week low of $120.17 and a 52-week high of $196.44. The stock’s 50-day moving average is $189.5 and its 200-day moving average is $179.9. The company has a market cap of $43.964 billion and a P/E ratio of 35.06.

McKesson (NYSE:MCK) last released its earnings data on Thursday, July 31st. The company reported $2.49 EPS for the quarter, beating the Thomson Reuters consensus estimate of $2.36 by $0.13. The company had revenue of $44.06 billion for the quarter, compared to the consensus estimate of $40.65 billion. During the same quarter last year, the company posted $2.07 earnings per share. McKesson’s revenue was up 36.7% compared to the same quarter last year. On average, analysts predict that McKesson will post $10.79 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which is scheduled for Wednesday, October 1st. Shareholders of record on Tuesday, September 2nd will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.51%. The ex-dividend date is Thursday, August 28th.

In other McKesson news, Director Marie L/Ca Knowles sold 785 shares of the company’s stock on the open market in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $192.10, for a total transaction of $150,798.50. The sale was disclosed in a filing with the SEC, which is available at this link.

A number of research firms have recently commented on MCK. Analysts at Credit Suisse reiterated an “outperform” rating on shares of McKesson in a research note on Monday, August 4th. They now have a $220.00 price target on the stock, up previously from $200.00. Separately, analysts at Zacks reiterated a “neutral” rating on shares of McKesson in a research note on Friday, August 1st. They now have a $201.00 price target on the stock. Finally, analysts at Leerink Swann raised their price target on shares of McKesson from $205.00 to $220.00 in a research note on Friday, August 1st.

McKesson Corporation delivers pharmaceuticals, medical supplies and healthcare information technologies.

Receive News & Ratings for McKesson Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson Co and related companies with Analyst Ratings Network's FREE daily email newsletter.